A Personalized Twist For Oncolytic Vaccines

Prospects for using viruses to fight cancer got a huge boost in late 2015 when the US Food and Drug Administration granted its first-of-a-kind approval of an oncolytic virus to treat advanced melanoma. Although the efficacy of the treatment, talimogene laherparepvec (T-VEC), was modest, its regulatory success has invigorated the field and dozens of other oncolytic viruses are now being tested in clinical trials.